[Trans-septo-sphenoidal operation for pituitary adenoma in 92 patients: results and follow-up endocrine studies].
The short- and long-term therapeutic results of transseptosphenoidal adenomectomy were studied retrospectively in 92 patients with pituitary tumors (42 nonsecreting adenomas, 21 GH-, 15 PRL-, 10 ACTH-, 2 TSH-, and 2 FSH-secreting adenomas). Severe surgically related complications were not observed. The early remission rate was 53.7% in nonsecreting, 57.1% in GH-secreting, 60% in PRL-secreting, 88.9% in ACTH-secreting, and 75% in TSH- or FSH-secreting adenomas. The recurrence rate in patients with nonsecreting adenomas was 47.1%, with GH-secreting adenomas 10%, with ACTH-secreting adenomas 25%, and with TSH- or FSH-secreting adenomas 66.7%, respectively. A long-term cure rate of 69.2% was observed in prolactinomas in combination with a facultative dopamine agonist therapy. More patients had normal pituitary function concerning TSH, ACTH, and LH/FSH post-operatively (48.9% versus 46.6% preoperatively). These data confirm that transseptosphenoidal surgery is a safe and selective treatment for pituitary adenomas with efficient preservation of the normal pituitary gland.
Gasser
R W
RW
Klinik für Innere Medizin, Universität Innsbruck.
Spoendlin
H
H
Finkenstedt
G
G
Pallua
A K
AK
Aichner
F
F
Braunsteiner
H
H
D000236:Adenoma / Q000378:metabolism / Q000601:surgery*; D000324:Adrenocorticotropic Hormone / Q000378:metabolism; D000328:Adult; D000368:Aged; D003480:Cushing Syndrome / Q000601:surgery; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000145:classification / Q000601:surgery*; D015175:Prolactinoma / Q000601:surgery*; D013101:Sphenoid Sinus / Q000601:surgery
D000324:Adrenocorticotropic Hormone